Allstate Corp Makes New $531,000 Investment in Hologic, Inc. $HOLX

Allstate Corp acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 7,861 shares of the medical equipment provider’s stock, valued at approximately $531,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Invesco Ltd. increased its position in shares of Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after buying an additional 3,505,828 shares during the period. K.J. Harrison & Partners Inc purchased a new stake in Hologic in the second quarter worth about $1,987,000. Aberdeen Group plc boosted its position in Hologic by 2.8% during the 2nd quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock valued at $15,964,000 after acquiring an additional 6,589 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Hologic by 7.2% during the 2nd quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock worth $168,674,000 after acquiring an additional 174,828 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Hologic during the 3rd quarter worth approximately $4,170,000. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research note on Friday, October 31st. BTIG Research reiterated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Finally, Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Three research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat.com, Hologic has an average rating of “Hold” and a consensus target price of $79.31.

Hologic Stock Performance

HOLX stock opened at $75.11 on Friday. The stock’s 50 day simple moving average is $74.78 and its 200 day simple moving average is $70.45. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.34. The stock has a market capitalization of $16.74 billion, a PE ratio of 30.29, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.03. The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 earnings per share. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.